SmithKline Beecham Australia Pty Ltd - s.87B undertaking

After conducting market inquiries, the Commission determined that the merger between SmithKline Beecham (Australia) Pty Ltd and Glaxo Wellcome Ltd, to form Glaxo SmithKline plc, would not substantially effect competition, provided that certain Undertakings be provided by SmithKline Beecham to the ACCC.

The Undertaking provides that SmithKline Beecham will sell its Famvir product to Novartis AG in the event that the merger proceeds.